Rybelsus Dosage Chart (2026): The Oral Semaglutide Titration & How to Take It

Rybelsus is oral semaglutide — the same molecule as Ozempic and Wegovy, but in a once-daily tablet instead of a weekly injection. It is titrated over three fixed steps: you start at 3 mg once daily for 30 days, increase to 7 mg once daily, and may then increase to a maximum of 14 mg once daily after at least another 30 days.^[1] The 3 mg starting dose is explicitly non-therapeutic — it exists only to let your gut adjust before you reach a dose that actually controls blood sugar. Just as important as the milligrams are the administration rules: Rybelsus must be swallowed on an empty stomach upon waking, with no more than a sip of plain water (≤4 oz / 120 mL), after which you wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines — because oral semaglutide is absorbed so poorly that breaking these rules sharply reduces how much drug reaches your blood.^[1] Note that Rybelsus is FDA-approved for type 2 diabetes, not weight loss — to improve blood sugar and, since an October 2025 label update based on the SOUL trial, to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes.^[1][4] The same label now also covers a newer, more absorbable Ozempic tablet (1.5 mg, 4 mg, 9 mg) that is not substitutable milligram-for-milligram with Rybelsus, and a separate once-daily Wegovy tablet (25 mg maintenance) is approved for weight reduction — both are covered below.^[1][5] This guide reproduces the full dose ladder, the strict timing rules, missed-dose handling, and what happens when 14 mg is not enough. All dosing here is illustrative of the FDA label — your prescriber sets your actual schedule. See our Ozempic drug page for the injectable form of the same molecule, the injectable semaglutide dosage chart for Wegovy/Ozempic, and the GLP-1 titration planner to map your own dates.

The Rybelsus dose ladder (3 mg → 7 mg → 14 mg)

Rybelsus (oral semaglutide, Novo Nordisk) was FDA-approved in September 2019 for type 2 diabetes. It comes as three tablet strengths — 3 mg, 7 mg, and 14 mg — and is taken once daily. (The current label also lists a separate Ozempic tablet in 1.5, 4, and 9 mg — a different formulation with its own ladder, covered further down.) Per the Rybelsus label §2.2, the titration is a simple three-step ladder, and the defining rule is that you spend at least 30 days at each of the first two doses before stepping up:^[1]

Read the ladder as: 3 mg for the first month is a "ramp-up only" dose, 7 mg is where treatment effectively begins, and 14 mg is the ceiling. The label is explicit that the 3 mg dose is not effective for glycemic control and is intended only for treatment initiation, and it instructs patients not to take more than one tablet per day — so the 14 mg maximum means a single 14 mg tablet, not two 7 mg tablets.^[1] Do not split, crush, chew, or dissolve any Rybelsus tablet.

The strict administration rules (empty stomach, ≤4 oz water, wait ≥30 minutes)

With Rybelsus, how you take the tablet matters as much as the dose. Oral semaglutide is absorbed very inefficiently from the gut, so the label builds in a set of timing rules that are not optional — breaking them can sharply reduce how much drug actually reaches your bloodstream. Per the Rybelsus label §2.1:^[1]

1. Take it first thing on waking, on an empty stomach — before any food, any other drink, or any other oral medication.
2. Swallow it whole with a sip of plain water only — no more than 4 oz (120 mL). Use water only; other liquids reduce absorption. Do not split, crush, chew, or dissolve the tablet.
3. Then wait at least 30 minutes before eating, drinking anything else, or taking any other oral medicines. Waiting less than 30 minutes lowers how much semaglutide is absorbed.

Why the 3 mg starting dose is non-therapeutic

The 3 mg starting dose can feel pointless — you take it for a full month and your blood sugar may barely move. That is by design. Per the label, the 3 mg dose is not effective for glycemic control and is intended only for treatment initiation; its single job is to improve gastrointestinal tolerability before you reach a dose that actually treats anything.^[1]

Semaglutide's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — and they are dose-related, worst when the dose first goes up. Starting at a sub-therapeutic 3 mg and holding it for 30 days lets the gut adapt, so that when you step up to the therapeutic 7 mg dose the nausea is far more manageable than it would be if you started at 7 mg on day one. The practical takeaways: do not skip the 3 mg month to "get to a working dose faster" (that predictably worsens nausea), and do not judge whether Rybelsus works while you are still on 3 mg — you are not yet at a therapeutic dose. If a step-up is not tolerated, talk to your prescriber rather than pushing on, skipping doses, or doubling up. You can map your escalation dates with the GLP-1 titration planner.

Rybelsus vs injectable semaglutide (Ozempic / Wegovy)

Rybelsus, Ozempic, and Wegovy are all semaglutide — the same molecule. But they are not interchangeable, and the milligram numbers do not translate across them:

• Route and frequency differ. Rybelsus is an oral tablet taken once daily; Ozempic and Wegovy are subcutaneous injections taken once weekly. The doses are on completely different scales — Rybelsus tops out at 14 mg per day, while injectable semaglutide tops out at 2.0 mg (Ozempic) or 2.4 mg (Wegovy) per week.
• Oral bioavailability is low. Semaglutide is a peptide, and peptides are normally destroyed in the gut. Rybelsus only works because each tablet includes an absorption-enhancing excipient — and even then, the label estimates absolute bioavailability at only about 0.4% to 1% for the 3, 7, and 14 mg Rybelsus tablets,^[1] which is exactly why the empty-stomach, plain-water, wait-30-minutes rules exist. This is why a Rybelsus milligram and an injected milligram are not the same thing.
• Doses are not interchangeable mg-for-mg. Because of that low and timing-sensitive oral absorption, you cannot convert a Rybelsus dose to an Ozempic or Wegovy dose (or vice versa) by matching milligrams. 14 mg of Rybelsus is not "the same as" any particular injectable dose — only your prescriber can switch you between formulations. The one injection-to-tablet switch the label spells out: a patient on Ozempic injection 0.5 mg weekly may start Rybelsus 7 mg or 14 mg daily one week after the last injection.^[1]
• Approved use differs. Rybelsus and Ozempic are FDA-approved for type 2 diabetes (for Rybelsus: glycemic control plus, since 2025, reducing major cardiovascular events in high-risk adults).^[1] Wegovy — now sold both as a weekly injection and as a once-daily tablet — is the semaglutide product FDA-approved for weight reduction.^[5] Rybelsus is not approved for weight loss.

For the full injectable ladder (Wegovy 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly and Ozempic 0.25 → 0.5 → 1.0 → 2.0 mg weekly), see our injectable semaglutide dosage chart and the Ozempic drug page. To compare providers that prescribe semaglutide, see the best semaglutide providers.

Rybelsus now carries a cardiovascular indication (the SOUL trial)

The Rybelsus label now lists a second indication: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events.^[1] It rests on SOUL, a double-blind trial that randomized 9,650 adults aged 50 or older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both to once-daily oral semaglutide (up to 14 mg) or placebo on top of standard care. A first major cardiovascular event occurred in 12.0% of the oral semaglutide group versus 13.8% of the placebo group (hazard ratio 0.86; 95% CI 0.77–0.96), while the confirmatory kidney secondary outcomes did not differ significantly between groups.^[4] The label reports a median follow-up of about 49.6 months.^[1] The dose ladder does not change for this indication — patients in the trial were randomized to the 14 mg tablet — so the 3 → 7 → 14 mg schedule and administration rules above still apply.

The newer oral semaglutide tablets: Ozempic tablets and Wegovy tablets

Two newer once-daily semaglutide tablets now sit alongside Rybelsus, and their milligram numbers are easy to confuse. Ozempic tablets are listed on the same label as Rybelsus, with the same type 2 diabetes indications, but use a reformulated tablet with an estimated absolute bioavailability of about 1% to 2% (versus about 0.4% to 1% for Rybelsus) — which is why its doses are lower. The label states plainly that Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis.^[1] Wegovy tablets are a separate product approved, with diet and physical activity, for weight reduction in adults with obesity or overweight with a weight-related condition, and to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.^[5] All three share the same empty-stomach, up-to-4-oz-of-water, wait-30-minutes routine and the one-tablet-a-day rule.^[1][5]

Switching between Rybelsus and Ozempic tablets is allowed only after the first 30-day initiation phase. The label's equivalence table pairs Rybelsus 7 mg with Ozempic tablets 4 mg and Rybelsus 14 mg with Ozempic tablets 9 mg, with the new product started the day after the old one is stopped.^[1] That means Ozempic tablets 9 mg is a like-for-like alternative to Rybelsus 14 mg, not a step up. Wegovy tablets are dosed for a different indication, and the Wegovy label says using it together with any other semaglutide-containing product or other GLP-1 receptor agonist is not recommended.^[5] Any change between these products is a prescriber decision.

Missed dose

Because Rybelsus is once daily, the label's missed-dose rule is simple:^[1]

• If you miss a dose, skip it entirely and take your next dose the following day. Do not take an extra tablet or double up to "catch up" — that does not improve control and increases the risk of GI side effects.
• Keep the same once-daily, on-waking, empty-stomach routine the next day, with the ≤4 oz plain-water sip and the 30-minute wait before food, drink, or other oral medicines.
• If you miss several days in a row, contact your prescriber. The label does not spell out a restart rule for multi-day gaps for Rybelsus. After a longer gap, tolerance to the GI effects can fade, and your prescriber may want you to restart at a lower step rather than resume the full dose — restarting high after a long pause can bring the nausea back.

When 14 mg isn't enough

14 mg once daily is the maximum Rybelsus dose — there is no higher Rybelsus tablet, and the label says not to take more than one tablet per day, so stacking tablets to "make" a higher dose is off-label.^[1] (Switching to Ozempic tablets 9 mg does not raise the dose either; the label treats it as the counterpart of Rybelsus 14 mg.) If blood sugar is still not adequately controlled on 14 mg once daily after an adequate trial, the next move is a prescriber decision, not a self-adjustment. Common options a clinician may consider include:

• Adding or optimizing another diabetes medication (for example metformin or other agents) alongside the Rybelsus, rather than exceeding 14 mg.
• Switching to injectable semaglutide (Ozempic) or another injectable GLP-1, which can reach effective exposures the oral tablet cannot — but, as above, the dose is chosen fresh by the prescriber, not converted milligram-for-milligram from Rybelsus.
• Re-checking adherence to the administration rules. Before concluding 14 mg "isn't enough," a prescriber will often confirm the empty-stomach, plain-water, 30-minute-wait routine is being followed exactly — because poor absorption from incorrect timing is a common reason oral semaglutide underperforms.

Whatever the next step, it belongs to your prescriber. To find a clinician for ongoing semaglutide prescriptions, compare the best semaglutide providers, or read our reviews of Found and Ro.